Welcome to our dedicated page for LMNGF news (Ticker: LMNGF), a resource for investors and traders seeking the latest updates and insights on LMNGF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LMNGF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LMNGF's position in the market.
BioVaxys Technology Corp. (OTCQB: BVAXF) announced a presentation of preclinical data for its SARS-CoV-2 vaccine candidate, BVX-0320, at the ISIRV-WHO Virtual Congress on October 19-21, 2021. The poster, authored by Chief Medical Officer David Berd, showcases significant antibody and T cell responses in a murine model. The company is advancing its haptenized viral protein technology and preparing for a clinical trial of its cancer vaccine. BioVaxys emphasizes that it does not claim ability to treat SARS-CoV-2 at this time.
BioVaxys Technology Corp. has initiated an in vivo animal toxicology study of its diagnostic tool, CoviDTH, in conjunction with an upcoming IND submission. The study, carried out by Inotiv, Inc., will assess the safety and toxicity of the SARS-CoV-2 s-protein used in CoviDTH. Although the FDA indicated that animal toxicity studies were not required, BioVaxys believes this data could be useful. CoviDTH is designed to evaluate T-cell immune responses in vaccinated or exposed individuals, reinforcing its potential as a low-cost, point-of-care diagnostic.
BioVaxys Technology Corp. announced the engagement of 6 Degrees, a communications firm, to enhance its strategic communications, public and media relations, and social media efforts. The President & COO, Kenneth Kovan, stated that this decision aligns with BioVaxys's growth and aims to increase public awareness. BioVaxys is focused on developing vaccines and diagnostics for viral and oncology applications, including a SARS-CoV-2 vaccine and cancer therapies. The company holds two US patents related to its cancer vaccine and has pending applications for its COVID-19 vaccine technologies.
BioVaxys Technology Corp. announced on September 20, 2021, that it has engaged 6 Degrees, a life sciences communications firm, to enhance its strategic communications and public relations efforts. The partnership aims to improve BioVaxys's visibility as the company advances its oncology and viral vaccine platforms, including a SARS-CoV-2 vaccine and a cell vaccine for ovarian cancer. BioVaxys holds two U.S. patents related to its cancer vaccine and is pursuing additional patents for its COVID-19 technologies.
BioVaxys Technology Corp. announced significant progress with cancer vaccine BVX-0918A, as manufacturing partner Bio Elpida in Lyon, France, completes key milestones in its development. The process now transitions to the next phase, focusing on a Quality by Design approach while preparing for GMP manufacturing. The vaccine aims to begin a Phase I clinical trial in Spain early next year. CEO Ken Kovan highlighted this achievement as a testament to their manufacturing partners' capabilities and a vital step for BioVaxys in advancing its oncology solutions.
BioVaxys Technology Corp. announced that WuXi Biologics has successfully synthesized recombinant SARS-CoV-2 s-protein for its COVID-19 vaccine candidate BVX-0320 and the CoviDTH immunodiagnostic product. Both products are set for clinical trials, with an IND submission to the FDA for CoviDTH underway. The company has confirmed high yields of the protein, essential for clinical studies, while the FDA noted that a preclinical animal toxicity study is not mandatory for IND submission. BioVaxys continues this study for additional data.
BioVaxys Technology Corp. announced the appointment of Dr. Charles J. Dunton as an Advisor to enhance scientific support for its ovarian cancer vaccine candidate BVX-0918A and the marketing of Papilocare in the U.S. Dr. Dunton, a gynecologist/oncologist with over 30 years of experience, has collaborated with BioVaxys on early clinical trials and is recognized as one of America's Top Doctors for Cancer. The decision aims to advance clinical studies and marketing efforts, reinforcing BioVaxys's strategy in the competitive immuno-oncology market.
BioVaxys Technology Corp. (CSE: BIOV, OTC: BVAXF) announced the appointment of Dr. Adam Coutts as Policy Advisor, effective May 20, 2021. Dr. Coutts, a Senior Research Fellow at the University of Cambridge, specializes in public health policy. CEO James Passin stated that Dr. Coutts' expertise will be crucial in advancing CoviDTH, a novel skin test for T cell immunity to Covid-19, through regulatory and commercial pathways. This low-cost solution aims to aid health systems in vulnerable settings, thereby optimizing vaccine distribution.
BioVaxys Technology Corp. (OTCQB: BVAXF) has announced its uplisting from the OTC Pink Sheets to the OTCQB Venture Market as of May 19, 2021. This mid-tier market is designed for early-stage companies, enhancing the visibility and liquidity of BioVaxys shares. CEO James Passin emphasized that this move will improve access to capital for the company's ongoing development of vaccines for ovarian cancer and COVID-19 diagnostics. BioVaxys currently has two issued patents and plans further clinical trials.
BioVaxys Technology Corp. announced a definitive bioproduction agreement with BioElpida S.A.S. for clinical-grade bioproduction of its ovarian cancer vaccine candidate, BXV-0918A. The agreement focuses on building a GMP facility in Lyon, France, and includes critical technical protocols. BioVaxys plans to submit a regulatory filing for a Phase I study by late 2021, with vaccine supply ready by May 2022. The ovarian cancer market is projected to grow from US$1.2B in 2017 to US$4.6B by 2026, indicating a strong need for innovative treatments in this area.
FAQ
What is the market cap of LMNGF (LMNGF)?
